Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02244307
Recruitment Status : Completed
First Posted : September 19, 2014
Last Update Posted : September 19, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers. The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.

Condition or disease Intervention/treatment
Prostatic Hyperplasia Drug: alpha-adrenergic blocker

Layout table for study information
Study Type : Observational
Actual Enrollment : 4561 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evolution of Patients Suffering From Benign Prostatic Hyperplasia (BPH) Treated With Alpha-adrenergic Blockade (JOSEPHINE)
Study Start Date : January 2000
Actual Primary Completion Date : June 2003

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with BPH treated with alpha-andrenergic blockade Drug: alpha-adrenergic blocker



Primary Outcome Measures :
  1. Assessment of prognosis factors for having recourse to prostatic surgery [ Time Frame: up to 2 years ]

Secondary Outcome Measures :
  1. Time form alpha-adrenergic blockade treatment initiation to surgery [ Time Frame: up to 2 years ]
  2. Occurrence of concomitant BPH diseases [ Time Frame: up to 2 years ]
  3. Total International Prostate Symptom Score (IPSS) [ Time Frame: up to 2 years ]
  4. Percentage of patients with ongoing BPH treatment [ Time Frame: up to 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with BPH for whom alpha-blockade treatement is indicated recruited at general practitioners
Criteria

Inclusion Criteria:

  • Any patient with BPH for whom alpha-blocker treatment is indicated
  • Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available

Exclusion Criteria:

  • Patient's follow-up not possible
  • Patients participating in another study
  • History of BPH surgery
  • Prostate cancer

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02244307     History of Changes
Other Study ID Numbers: 527.28
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Hyperplasia
Hyperplasia
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs